Stockscreener 앱 받기
8.66
0.81%
0.07
시간 외 거래:
8.61
-0.05
-0.58%
CorMedix Inc 주식(CRMD)의 최신 뉴스
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath MomentumLearn Why - Yahoo Finance
CorMedix Inc. (CRMD) Reports Q1 2026 Results - Insider Monkey
CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake - Stock Titan
CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake - Stock Titan
5 Most Profitable Small Cap Stocks to Buy - Insider Monkey
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
CRMD Q1 2026 Earnings: EPS Beat of 31.72% Drives Stock HigherProfit Recovery Report - newsline.com
Federal appeals court upholds CorMedix patent win over Nexus - Investing.com UK
Federal Circuit Affirms CorMedix Patent Victory, Blocking Nexus Generic MINOCIN® Launch Until Patent Expiration 1 - minichart.com.sg
Federal appeals court upholds CorMedix patent win over Nexus By Investing.com - Investing.com South Africa
Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN® patents and injunction - Stock Titan
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation - Yahoo Finance
Can CorMedix Turn Launch Execution Into Momentum? - Kalkine Media
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CRMD Q1 2026 Earnings: Strong EPS Beat Drives Stock HigherPost-Earnings Drift - newsline.com
CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN
CRMD Technical Analysis | Trend, Signals & Chart Patterns | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CRMD Q1 2026 Earnings: Strong EPS Beat as Company Advances Commercial EffortsNet Profit Margin - newsline.com
Avoiding Lag: Real-Time Signals in (CRMD) Movement - Stock Traders Daily
CRMD Q1 2026 Earnings: Positive EPS Surprise Despite Absence of RevenueGross Profit Margin - The Legal Advocate
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
CorMedix: Bleak Short-Term Outlook, But Significantly Undervalued For The Long Run - Seeking Alpha
Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN
CorMedix Q1 earnings call highlights - MSN
CorMedix (CRMD) Tests Support Zone After Modest DeclineFade Trade - newsline.com
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView
CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - MarketBeat
CorMedix stock jumps as DefenCath fuels Q1 beat, 2026 outlook raised - MSN
Cormedix Earnings Call Highlights Surging Growth, New Risks - TipRanks
CorMedix banks on DefenCath sales in Q4 as Melinta adds upside - MSN
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD - MarketBeat
Needham Maintains CorMedix (CRMD) Buy Recommendation - MSN
Discipline and Rules-Based Execution in CRMD Response - Stock Traders Daily
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance
CorMedix Inc $CRMD Shares Bought by Vanguard Group Inc. - MarketBeat
RBC Capital Keeps Their Buy Rating on Cormedix (CRMD) - The Globe and Mail
CorMedix (CRMD) Q1 earnings and revenues beat estimates - MSN
CorMedix Inc.Common Stock (NQ: CRMD - The Chronicle-Journal
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - The Globe and Mail
A Quick Look at Today's Ratings for CorMedix(CRMD.US), With a Forecast Between $13 to $15 - Moomoo
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership - Stock Titan
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences - marketscreener.com
1.27%
1.43%
자본화:
|
볼륨(24시간):